Enhance Your Vision With Minimally Invasive Glaucoma Surgery
What Is Minimally Invasive Glaucoma Surgery
Minimally invasive glaucoma surgery, commonly known as MIGS, represents a significant advancement in how we manage glaucoma, offering effective pressure reduction with a gentler approach than traditional surgical options. These procedures use tiny devices and micro-incisions to improve the natural drainage of fluid inside the eye, helping to slow or halt the progression of glaucoma-related vision loss. At Greenwich Ophthalmology Associates, our fellowship-trained glaucoma specialists provide a full range of MIGS procedures tailored to each patient's condition, lifestyle, and treatment goals. Whether you are exploring surgical options for the first time or looking to reduce your dependence on daily eye drops, MIGS may offer a path toward more comfortable and effective glaucoma management.
MIGS refers to a group of surgical procedures that lower intraocular pressure (IOP) using microscopic devices and techniques performed through tiny incisions inside the eye.
Traditional glaucoma surgeries such as trabeculectomy and tube shunt implantation are highly effective but carry a higher risk of complications and require more extensive recovery periods. MIGS was developed to fill the gap between medication or laser therapy and these more invasive procedures. By working at the microscopic level, MIGS procedures achieve meaningful pressure reduction with less tissue disruption, making them appealing for a wide range of patients with glaucoma.
MIGS procedures share several features that distinguish them from conventional glaucoma surgery. They are typically performed through a clear corneal incision using an ab interno approach, meaning the surgeon operates from inside the eye rather than cutting through the outer wall. This technique involves minimal manipulation of the conjunctiva and sclera, preserving these tissues for potential future procedures if needed. Recovery is generally faster, and the overall risk profile is lower compared to traditional glaucoma surgery.
MIGS devices and techniques are categorized by the outflow pathway they target. The major approaches include:
- Trabecular bypass devices that create a direct pathway through the trabecular meshwork into Schlemm's canal
- Canal scaffolding devices that hold Schlemm's canal open to improve natural drainage
- Subconjunctival filtration devices that redirect fluid to a space beneath the conjunctiva
- Tissue removal procedures, such as goniotomy, that excise a portion of the trabecular meshwork to reduce outflow resistance
How MIGS Works to Lower Eye Pressure
Understanding how fluid moves through your eye helps explain why MIGS is effective at reducing the pressure that damages the optic nerve in glaucoma.
Your eye constantly produces a clear fluid called aqueous humor, which nourishes internal structures like the lens and cornea before draining out through a network of channels near the front of the eye. When these drainage pathways become blocked or less efficient, fluid accumulates and intraocular pressure rises. Over time, elevated pressure can damage the optic nerve fibers responsible for both your peripheral and central vision.
Most MIGS procedures work by improving aqueous outflow through the eye's existing drainage system. Trabecular bypass stents, such as the iStent inject W, create a direct channel through the trabecular meshwork, the tissue most responsible for outflow resistance. Canal-based devices like the Hydrus Microstent open and scaffold Schlemm's canal so fluid can reach the collector channels more efficiently. These approaches take advantage of the anatomy your eye already has rather than creating an entirely new drainage route.
Some MIGS devices redirect fluid to different drainage sites altogether. The XEN Gel Stent, for example, creates a new pathway that channels aqueous humor to the subconjunctival space, similar in concept to trabeculectomy but with a less invasive implantation technique. This option is particularly useful for patients with moderate-to-advanced glaucoma who need greater pressure reduction than trabecular bypass devices typically provide.
Who Is a Candidate for MIGS
MIGS can benefit a broad range of glaucoma patients, though certain factors help our glaucoma specialists determine which procedure and device offer the best fit.
Most MIGS procedures are designed for patients with mild-to-moderate open-angle glaucoma who need better pressure control than medications or laser therapy alone can provide. If you are using one or more eye drops and your pressure remains above your target, or if you experience bothersome side effects from your current medications, MIGS may help achieve a lower pressure with fewer drops.
Many MIGS devices are FDA-approved for implantation during cataract surgery, making this an ideal time to address both conditions in a single procedure. Combining MIGS with cataract removal adds only a few minutes to the operation and typically does not change your recovery experience. This combined approach is one of the most common and convenient ways patients first benefit from MIGS.
For patients who struggle with the cost, inconvenience, or side effects of daily glaucoma drops, MIGS can meaningfully reduce the number of medications needed. Clinical studies have shown that many patients use fewer drops following MIGS, and some are able to discontinue drops entirely. Results vary by individual, and our glaucoma specialists will set realistic expectations based on your specific condition and pressure goals.
Patients with advanced or aggressive glaucoma who require very low target pressures may benefit more from traditional filtration surgery, which typically achieves greater overall pressure reduction. Similarly, certain types of glaucoma, such as neovascular or inflammatory glaucoma, may not respond as well to standard MIGS devices. A thorough evaluation that includes visual field testing, optic nerve imaging, and a review of your treatment history helps our team recommend the most appropriate surgical path.
What to Expect During and After MIGS
MIGS procedures are performed in an outpatient setting, and most patients return to their normal activities within a few days.
Your preoperative preparation will include a comprehensive eye examination with detailed measurements of your eye pressure, optic nerve health, and visual field function. Our glaucoma specialists will review your current medications, discuss which MIGS device is best suited for your condition, and explain the expected benefits and risks. If your MIGS will be combined with cataract surgery, lens measurements will also be taken at this visit.
MIGS is performed under local or topical anesthesia, meaning you remain awake but comfortable throughout. The surgeon uses a specialized microscope and a goniolens to visualize the internal drainage structures of the eye. The micro-device is then placed through a tiny corneal incision, with the MIGS portion of the procedure typically taking only a few minutes. Most patients report feeling little to no discomfort during the process.
You can expect mild soreness, light sensitivity, and slightly blurred vision for the first few days following surgery. Your surgeon will prescribe anti-inflammatory and antibiotic eye drops to support healing and prevent infection. Most patients resume driving and light daily activities within one to three days. A series of follow-up visits over the first several weeks allows our team to monitor your pressure response and adjust any remaining glaucoma medications as needed.
Even after a successful MIGS procedure, ongoing monitoring remains essential. Glaucoma is a lifelong condition, and regular check-ups ensure that your pressure stays at a safe level and that no further intervention is needed. For a broader look at how MIGS fits into your overall treatment plan, our comprehensive MIGS guide provides additional detail on long-term management and follow-up expectations.
Frequently Asked Questions
Several FDA-approved MIGS devices are in use today. The iStent inject W is a trabecular bypass micro-stent, the Hydrus Microstent scaffolds Schlemm's canal to improve drainage, and the XEN Gel Stent diverts fluid to the subconjunctival space for patients who need a greater reduction in pressure. Goniotomy instruments such as the Kahook Dual Blade and the OMNI Surgical System also fall under the MIGS category. Each device targets a different part of the drainage pathway, and the best choice depends on your glaucoma type, severity, and whether the procedure will be combined with cataract surgery.
Many patients are able to reduce the number of glaucoma drops they use after MIGS, and a meaningful percentage can stop drops entirely. For example, clinical trials for the Hydrus Microstent showed that a majority of patients remained medication-free at two years. However, individual results depend on your baseline pressure, disease severity, and target pressure, so some patients will still benefit from using one or more drops after surgery.
MIGS generally offers a faster recovery, fewer activity restrictions, and a lower risk of serious complications compared to trabeculectomy or tube shunt procedures. The tradeoff is that most MIGS devices produce a more modest reduction in eye pressure, making them best suited for mild-to-moderate glaucoma. Patients with advanced disease who need pressures in the low single digits may still be better served by traditional filtration surgery.
MIGS carries a favorable safety profile compared to conventional glaucoma surgery. Possible risks include temporary bleeding inside the eye (known as hyphema), transient pressure spikes, mild inflammation, and, in rare cases, device malposition. Serious complications such as infection or significant vision loss are uncommon. Our glaucoma specialists discuss all potential risks with you during your preoperative consultation so you can make a fully informed decision.
Published clinical data suggest that most MIGS devices maintain their pressure-lowering benefit for at least three to five years. The HORIZON trial for the Hydrus Microstent, one of the longest running MIGS studies, demonstrated sustained pressure reduction and medication independence through five years of follow-up. If the effect diminishes over time, additional interventions such as laser treatment, medication adjustments, or further surgery remain available options.
Most MIGS procedures are covered by Medicare and major commercial insurance plans, particularly when performed in combination with cataract surgery. Coverage for standalone MIGS can vary by insurer and by the specific device used. Our team can help verify your insurance benefits and discuss any expected out-of-pocket costs well before your scheduled procedure date.
Take the Next Step Toward Better Glaucoma Care
Minimally invasive glaucoma surgery has given many patients a way to manage their condition with less reliance on daily eye drops and a quicker return to everyday life. Our board-certified, fellowship-trained glaucoma specialists at Greenwich Ophthalmology Associates in the greater NY/CT region are here to help you understand your options and determine whether MIGS is the right choice for your eyes. If you are living with glaucoma and would like to explore surgical options, we welcome the opportunity to provide a thorough evaluation and a personalized treatment recommendation. Scheduling a consultation is the first step toward protecting your vision for the years ahead.
We encourage you to bring your questions and concerns to your next appointment so we can develop a care plan that addresses your goals and lifestyle.
Learn More About Related Topics
To further your understanding, explore our resources on Glaucoma Surgery Combined with Cataract Surgery, Glaucoma Laser Surgery, and Glaucoma Surgery Recovery: A Complete Timeline.
You may also find these pages helpful: Glaucoma Surgery: Types, Risks & Recovery, Glaucoma Treatment Options: Drops, Laser and Surgery, and MIGS and Traditional Glaucoma Surgery.
What our Patients say
4.8
Reviews
(3645)